Unlock the value of Qiagen

Davidson Kempner considers Thermo Fisher Scientific’s offer to acquire QIAGEN to severely undervalue the company and will not tender its shares into the offer.

See the latest information on the Content Hub. All latest materials are posted here.

Sign-up and stay informed.

We will notify you of any updates via email.